Outcomes of haploidentical versus matched related donor allogeneic stem cell transplantation in patients with myelodysplastic syndromes: A single-center retrospective cohort study
Therapeutic Advances in Hematology · 2026-11 · 17
DOI: 10.1177/20406207261504656 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 13.11.2026. Verfasst von Xiaojun Zhao und 10 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Hebei Province, Special Fund for Excellent Health and Healthcare Talents and High-Quality Development of Public Hospitals Sponsored by the Hebei Provincial Government, Fund for the Prevention and Treatment of Geriatric Diseases Sponsored by the Hebei Provincial Government.
Abstract (Originalsprache)
Background
Myelodysplastic syndromes (MDS) patients without matched donors face therapeutic challenges. Haploidentical donors (HID) emerge as potential alternatives, but comparative outcomes remain understudied.
Objectives
To compare the clinical outcomes of matched related donor (MRD) and HID allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of MDS.
Design
Single-center retrospective cohort study (2014-2021).
Methods
29 MDS patients undergoing allo-HSCT were divided into HID (n=14) and MRD (n=15) groups. Outcomes including engraftment rates, engraftment times, transplant-related mortality (TRM) and complications, overall survival rates, and disease-free survival were compared between the two groups to evaluate the efficacy of the two approaches.
Results
The incidence of acute graft- versus -host disease (aGVHD) was higher in the HID group compared to the MRD group (P > 0.05), especially in grade III-IV aGVHD (P = 0.02). There were no significant differences in baseline characteristics, counts of infused hematopoietic stem cells, engraftment times, chimerism, transplant-related complications (excluding grade III aGVHD), 2-year overall survival (OS2Y), and 2-year disease-free survival (DFS2Y) between the two groups (P > 0.05).
Conclusions
Haploidentical donor allo-HSCT demonstrates comparable efficacy to matched related donor allo-HSCT in the treatment of MDS. HID allo-HSCT may be considered as an alternative for patients who cannot find a matched related donor or matched unrelated donor in the bone marrow registry.
Förderung
- Natural Science Foundation of Hebei Province
- Special Fund for Excellent Health and Healthcare Talents and High-Quality Development of Public Hospitals Sponsored by the Hebei Provincial Government
- Fund for the Prevention and Treatment of Geriatric Diseases Sponsored by the Hebei Provincial Government
Zitieren
APA
Zhao, X., Ma, Z., Liu, W., Zhang, L., Guo, X., Niu, Z., Ma, F., Wang, F., Ren, J., Zhang, X., & Wang, Y. (2026). Outcomes of haploidentical versus matched related donor allogeneic stem cell transplantation in patients with myelodysplastic syndromes: A single-center retrospective cohort study. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261504656
Vancouver
Zhao X, Ma Z, Liu W, Zhang L, Guo X, Niu Z, et al. Outcomes of haploidentical versus matched related donor allogeneic stem cell transplantation in patients with myelodysplastic syndromes: A single-center retrospective cohort study. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261504656
BibTeX
@article{Zhao2026,
author = {Zhao, Xiaojun and Ma, Ziwei and Liu, Weiwei and Zhang, Linlin and Guo, Xuefei and Niu, Zhiyun and Ma, Futian and Wang, Fuxu and Ren, Jinhai and Zhang, Xuejun and Wang, Ying},
title = {Outcomes of haploidentical versus matched related donor allogeneic stem cell transplantation in patients with myelodysplastic syndromes: A single-center retrospective cohort study},
journal = {Therapeutic Advances in Hematology},
year = {2026},
volume = {17},
doi = {10.1177/20406207261504656}
}
EUVIMED